{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Hematologic Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39"}]}],"title":"Hematologic Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"title":"Non-Hematologic Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Non-Hematologic Grade 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"Count of participants with grade 3/4 hematologic and non-hematologic adverse events.","groups":[{"description":"Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8, carboplatin IV over 30-60 minutes on day 1, and dexamethasone orally (PO) on days 1-4. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CD20-POSITIVE LYMPHOMAS also receive rituximab IV on day 8.","id":"OG000","title":"Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"3-4 weeks after completion of study treatment","title":"Hematologic and Non-hematologic Adverse Events.","type":"SECONDARY","unitOfMeasure":"Participants"}